Wegovy Microdosing: The Real Story and 5 Actual Options in 2026

Is there such a thing as a Wegovy microdose?

No — and that correction is worth sitting with before anything else, because it changes what you're actually shopping for. Wegovy is Novo Nordisk's trademarked, FDA-approved brand of semaglutide for chronic weight management. It ships in exactly one kind of device: a single-dose, pre-set autoinjector with no dial and nothing to adjust — a deliberate design choice, unlike its sibling drug Ozempic's dial-adjustable pen. NovoCare, the company's own pharmacy and savings program, sells Wegovy at its standard FDA-reviewed doses and nothing smaller. There is no "Wegovy microdose" SKU on wegovy.com, novocare.com, or anywhere else Novo Nordisk controls.

If anything, the company's own product line has been moving in the opposite direction. In March 2026, the FDA cleared a new 7.2mg strength — branded Wegovy HD — for patients who've already plateaued on the standard 2.4mg maintenance dose and need more, not less. That's the real trajectory of Novo Nordisk's dose ladder: upward, for people who've built tolerance, not downward into a gentler starting point.

• Wegovy = Novo Nordisk's trademarked, FDA-approved semaglutide brand for chronic weight management. No manufacturer microdose version exists.
• The Wegovy pen is a single-dose, pre-set autoinjector — not built to be split, drawn from, or dosed below its lowest FDA strength.
• When a telehealth ad, influencer, or Reddit thread says "Wegovy microdosing," it's virtually always describing compounded semaglutide — a different, pharmacy-made product, not the branded pen.

Where can you actually get semaglutide microdosing sold as "Wegovy"?

Strip away the branding confusion and the actual market narrows fast. A handful of telehealth platforms sell a real, named, separately priced compounded-semaglutide microdose product — not Wegovy, but the same active molecule, at a fraction of its labeled dose. Five have pricing solid enough to table here.

Mochi Health — no dedicated SKU, and the lowest total price

Mochi doesn't brand a separate microdose product at all. Compounded semaglutide is one flat $99-a-month medication fee across its entire dose range, plus a $79 membership covering its ABOM-certified physician network — about $178 all-in. A prescriber choosing to keep your dose low and your titration slow doesn't change what you owe; it's simply the bottom of the standard plan, which happens to make it the cheapest route on this page even without a dedicated product to point to.

Henry Meds — the cheapest dedicated microdose product

Henry Meds runs an actual, separate Semaglutide Microdose page, priced at $179 a month with visits, medication, and supplies folded into that single rate — no membership fee stacked on top. Of the platforms that sell microdosing as its own named product rather than a titration choice buried in a standard plan, it's the cheapest.

Noom's Microdose GLP-1Rx — the most established name in this space

Noom built the best-known branded version of semaglutide microdosing, distinct from its standard GLP-1Rx tier. Current pricing runs $49 for the initial four-week supply, then $179 a month afterward — though it isn't billed monthly at all; Noom charges it as a lump sum roughly every 12 weeks, close to $537 a quarter, so budget for that rather than assuming a smaller recurring charge. Noom defines the program's dose as 25% or less of a typical maintenance dose, commonly landing around 0.2mg to 0.6mg weekly and set individually by a prescriber. Worth knowing given how much this specific brand gets searched: Noom's marketing around this product has already drawn regulatory scrutiny once, after a competitor challenged one of its dose-related claims — a reminder that commercial popularity here isn't the same thing as a settled clinical claim.

Lemonaid Health — the same 25% framing as Noom, billed in two lines

Lemonaid sells a compounded semaglutide microdose capped at 25% of standard maintenance dose — the same definition Noom uses independently, which suggests something closer to an informal industry convention forming here rather than a coincidence. The bill comes in two separate line items: $199 for the medication and $49 for membership, about $248 all-in — the second-highest total of the five, though still well under Wegovy's own self-pay pricing.

Fridays — wellness framing, not weight-loss framing

Fridays runs a genuinely separate "Microdosing" product line, apart from its standard weight-loss semaglutide track, and leans hardest into wellness language of the five: energy, metabolic balance, and mental clarity rather than pounds lost. The daily oral compounded semaglutide formulation runs $249 a month at the month-to-month rate — the highest of the five once billed that way. Fridays' standard weight-loss track offers a cheaper annual-prepay tier; it's worth checking directly whether the same discount applies to this specific microdosing product before assuming it doesn't.

Two names worth actively ruling out, since they show up constantly in searches for this: Ro's own site currently sells only brand-name product — Wegovy pen, Zepbound, and generic semaglutide — with no compounded or microdose option listed anywhere on its weight-loss pages. And Hims settled its dispute with Novo Nordisk in March 2026 and exited compounded semaglutide for new patients; it now sells FDA-approved Wegovy (injectable and oral) and Zepbound at standard doses, not a microdose product. If you're seeing either name attached to "Wegovy microdosing" content, that's likely stale or general-education content, not something either company currently sells.

One more worth a mention: WeightCare advertises a semaglutide micro-dose program running from 0.25mg up toward a 1mg ceiling, but its pricing was inconsistent across sources during this research and isn't confirmed cleanly enough to table here — check directly before treating any figure you see for it as final.

What does Wegovy-style microdosing cost per month — and per year?

None of the five differs wildly once annualized, but the gap against actual Wegovy is the number that matters. Set side by side, annually:

• Mochi Health (~$178/mo all-in): ~$2,136/year — the lowest total here.
• Henry Meds ($179/mo): ~$2,148/year.
• Noom's Microdose GLP-1Rx ($49 to start, then $179/mo, billed quarterly): ~$2,148/year — lands close to Henry Meds despite the lower sticker price, since it's a lump sum every 12 weeks rather than truly monthly.
• Lemonaid Health ($199 medication + $49 membership): ~$2,976/year.
• Fridays (Daily Oral Semaglutide Microdosing, $249/mo): ~$2,988/year — the highest of the five.
• NovoCare self-pay Wegovy, no insurance ($349/mo ongoing after a $199 introductory rate, or $399/mo for Wegovy HD): ~$4,188/year at the standard maintenance dose.
• Wegovy full retail, no program at all (~$1,349/mo): ~$16,188/year — a number almost nobody who's shopping around actually pays.
• NovoCare savings card, commercially insured (~$25/mo): ~$300/year — the cheapest path of all, and nothing on this page beats it if you qualify.

Compounded semaglutide microdosing sits well below NovoCare's self-pay tier and dramatically below full retail, but it's genuinely more expensive than the savings card for anyone who's eligible for it. None of these figures include labs if your prescriber orders them separately. For the complete brand-name pathway breakdown, see Wegovy cost.

Is it legal to microdose Wegovy, or is this actually compounded semaglutide?

It's compounded semaglutide, and the distinction is a legal one, not just a marketing one. Wegovy's trademark protects the finished, FDA-approved product — the name, Novo Nordisk's manufacturing process, and the agency's review of that exact formulation. No compounding pharmacy has a legal path to copy that and sell it as "Wegovy," at any dose. What a licensed 503A pharmacy can legally do is compound the active molecule under its own generic name, semaglutide, for a specific patient with a documented clinical reason the commercial product doesn't meet. Novo Nordisk has been aggressive about defending that line specifically for Wegovy — the company has filed well over 100 lawsuits against compounders, med spas, and telehealth sellers, and in April 2025 won a permanent injunction against one compounding pharmacy that had marketed knockoff drugs as Wegovy, with court-ordered disclosures telling patients the products were never FDA-reviewed.

Compounded semaglutide's own legal footing has narrowed since the shortage years that made it common everywhere. The FDA declared semaglutide's shortage resolved in February 2025, which wound down broad 503A and 503B compounding by mid-2025. What remains is a narrower pathway: compounding for a documented, individual clinical need the approved version can't meet — not simply because it's cheaper. In April 2026, the FDA went further, proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List entirely; the public comment period, after an extension, closed July 30, 2026, and no final rule had been issued as of this writing. That proposal targets 503B bulk compounding specifically, which had already wound down — it doesn't change the narrower 503A pathway every provider above uses.

A provider that markets its product literally as "Wegovy microdosing" or "compounded Wegovy," rather than clearly saying compounded semaglutide, is misusing a trademark Novo Nordisk actively sues over — and it's itself a signal worth taking seriously about how the rest of that business operates.

How does Wegovy's real FDA dose ladder compare to a "microdose"?

Wegovy's approved escalation schedule is the reference point every microdose product gets measured against, whether the marketing says so or not. It climbs in five steps to a 2.4mg maintenance dose over a minimum of 16 weeks, with a newer 7.2mg strength available afterward for those who've plateaued. A compounded semaglutide microdose, in the sense these platforms sell it, means staying well under even the first rung of that ladder — not just at the early tolerability steps, but below them entirely.

For the full ladder, the separate oral-tablet schedule, and missed-dose rules, see the Wegovy dosage chart.

Is there evidence microdosing works, or is it mostly marketing?

Mostly a trend, with a real mechanism underneath it. Semaglutide acts on a single receptor — GLP-1 — and that well-understood pharmacology is part of why researchers can reasonably expect a dose-response relationship to hold at lower amounts too. What's missing is the trial that actually tested that expectation. STEP-1, the study behind Wegovy's approval, was built around reaching a 2.4mg maintenance dose, with a clear pattern of more drug producing more weight loss up to that ceiling. Deliberately staying well under the starting dose long-term wasn't the protocol STEP-1 tested, and there's no completed clinical trial specifically evaluating semaglutide microdosing for weight loss as of this writing.

That gap matters more here because this corner of the GLP-1 conversation is unusually commercially developed — five real companies have built priced products and marketing around it. Commercial traction isn't clinical evidence, and it's worth holding the two apart when you're deciding whether a lower dose is a reasonable starting point or a claim outrunning what's actually been studied.

Are side effects actually gentler at a lower dose?

Probably somewhat, though not proven at the specific doses these platforms sell. In the trials behind Wegovy's approval, nausea and GI side effects were heaviest right after each dose increase and eased with time — a pattern that lines up with expecting a smaller dose to feel easier, since there's less of an increase to adjust to. But that's an extrapolation from data collected at 0.25mg and above, not a measurement taken at 0.1mg or 0.2mg specifically. Some platforms cite their own internal figures on tolerability, but that's self-reported company survey data, not an independently measured trial result, and figures like that tend to run more favorable than clinical measurement typically does.

On effectiveness, the honest answer gets less certain the lower you go. STEP-1's results were measured at the 2.4mg maintenance dose specifically. Staying meaningfully below that is an off-label choice with a thinner evidence base — some people do see real appetite and weight changes at lower doses, but how much benefit holds up at a quarter of the studied dose, consistently, isn't well established yet.

Is this a smart starting point for you in perimenopause?

If your GI system already feels more reactive than it used to — and a lot of women notice perimenopause turning up the volume on nausea and bloating that never bothered them before — a gentler on-ramp has real appeal, and a slower climb genuinely can mean fewer rough early weeks. It carries a related upside worth knowing: pacing weight loss more slowly tends to be easier on muscle, which matters more once estrogen decline is already working against your lean mass on its own. That specific tradeoff, and how to protect against it regardless of which dose you land on, is covered in GLP-1s and muscle loss in perimenopause.

The honest counterweight: choosing to stay at a fraction of the studied dose trades away some certainty about results for that gentler start. If meaningful weight or metabolic change is your main goal, climbing toward Wegovy's own studied 2.4mg maintenance dose — under NovoCare or with insurance coverage — has the stronger evidence behind it. A slower climb toward that same destination, rather than stopping well short of it, is a middle path worth raising with your prescriber if side effects, not the outcome, are what worries you. For the broader hormonal picture behind weight change in this decade of life, see GLP-1 medications and menopause weight gain.

How to tell a legitimate low-dose protocol from a DIY red flag

The line that matters isn't the number on the dose — it's who's managing it. A legitimate microdose protocol comes from a licensed prescriber, filled through a named 503A compounding pharmacy, with a dose your provider set and can adjust as you go. A red flag looks different: splitting a Wegovy pen yourself (a device that isn't designed for it), buying an unlabeled "microdosing kit" online, or drawing a reduced amount from a vial without specific instructions from anyone who's reviewed your history.

The FDA has already documented what goes wrong with the self-directed version. A July 2024 alert on compounded semaglutide dosing errors described patients accidentally injecting five to twenty times their intended dose after misreading units on a syringe, some requiring hospitalization — a risk specific to compounded vial-and-syringe formulations, not the pre-filled Wegovy pen, which delivers a fixed amount and isn't built for splitting or repeated draws. If a seller can't name its compounding pharmacy or explain the specific clinical-need pathway it's using, that's the moment to walk away rather than adjust anything yourself.